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Abstract
Background: Heatstroke is a life-threatening condition defined by failure of heat load dissipation, resulting in a core
temperature higher than 40 °C (104 °F) associated with neurological dysfunction. Topiramate may cause anhidrosis,
potentially resulting in heatstroke, as reported especially in children.
Case presentation: A 57-year-old Caucasian man was admitted to the emergency room in a febrile comatose state.
After a complete workup ruling out the usual etiologies of such a condition, we assumed the hypothesis of
a heatstroke caused by topiramate, recently prescribed for essential tremor.
Conclusions: Topiramate-related heatstroke has been described in children but must be recognized in adults
as well. Outcomes may range from total clinical recovery to persistent neurological dysfunction or death. The
prescription of topiramate and the follow-up of adult patients under this medication should include an evaluation of
hypohidrosis, especially in contexts of high temperature.
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Background
Heatstroke is a life-threatening condition defined by
failure of heat load dissipation, resulting in a core
temperature higher that 40 °C (104 °F) associated
with neurological dysfunction, ranging from mild al-
tered mental status to coma [1]. Mortality is high
among patients presenting to the hospital. Two types
can be distinguished, exertional and classical heat-
stroke. Exertional heatstroke is related to strenuous
exercise during periods of high temperature. Classical
heatstroke is favored by any mechanism decreasing
heat loss (anticholinergic or antihistamine drugs, ad-
vanced age, high ambient temperature,…) or increas-
ing heat production (sepsis, stimulant drugs, thyroid
storm,…). Multiple organ complications are common,
including acute respiratory distress syndrome, acute
renal failure, hepatic injuries, and rhabdomyolysis.
Topiramate has been described as a trigger for heat-
stroke, essentially in epileptic children, leading to an
FDA warning about monitoring patients on topiramate
in case of hot weather. We present here the case of a
topiramate-associated heatstroke in an adult patient suf-
fering from essential tremor.
Case presentation
A 57-year-old Caucasian man was admitted to the
emergency room in a febrile comatose state. He was
working as a chimney sweep and was known for hyper-
tension, type II diabetes, dyslipidemia and essential
tremor for which he had been prescribed topiramate 6
weeks earlier, at an initial dosage of 25 mg per day. The
dosage was progressively increased by his physician, up
to 50 mg twice a day on the day of admission. Other
medication included citalopram, clonazepam, allopurinol,
ibuprofen, mefenamic acid, metformin, esomeprazole, pro-
pranolol, losartan, torasemide, and hydrochlorothiazide.
Our patient was admitted in July, and the
temperature on the day of his admission reached 39.7 °C
(103.4 °F, heat index >93). The mean temperature of
the week before was 36.6 °C (97.3 °F), making this
week the second warmest week noted in Switzerland
for more than 150 years, according to the national
meteorological station [2].
Earlier on that day, as he was walking toward his car
after work, our patient suddenly lost consciousness. At
the arrival of the ambulance, our patient was found in a
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comatose state, with a Glasgow Coma Score (GCS) of 3.
He was tachypneic with a rate of 50 breaths per minute
with a preserved oxygen saturation and his tympanic
temperature was more than 41 °C (105.8 °F), reaching the
maximal scale of the thermometer. His blood pressure
was 110/62 mmHg and his heart rate was 89 beats
per minute. The onsite glycemia was 10 mmol/L. He
was intubated and then brought to the emergency
room. Given these circumstances, the initial neuro-
logic examination was limited, but showed no asym-
metrical pattern, no clonus, and no hyperreflexia.
On arrival, his temperature was 40.4 °C (104.7 °F) and
he became hemodynamically shocked, needing volume
resuscitation with 4 liters of sodium chloride 0.9 % and
administration of noradrenaline. The electrocardiogram
showed ventricular bigeminy and he received intra-
venous magnesium. Ceftriaxone and acyclovir were
administrated, given a primary hypothetical diagnosis
of meningoencephalitis.
Table 1 depicts the blood analyses at admission and a
few hours later. They reflect a progressive multiple
organ failure developing within 48 hours. A brain and
thoracoabdominal computed tomography (CT) scan
with injection of radiocontrast media showed no abnor-
malities except nonspecific, basilar pulmonary infiltrates
of limited interest to explain our patient’s condition.
Echocardiography showed a normal left ventricular ejec-
tion fraction and no pericardial effusion.
A lumbar puncture showed an albuminocytologic
dissociation (1 M/L leukocytes, 0.72 g/L proteins)
without oligoclonal distribution, and an augmented
glycorrachia (5 mmol/L). Cultures of the cerebrospinal
fluid (CSF) remained sterile and viral polymerase chain re-
action (PCR) assays [enteroviruses, human immunodefi-
ciency virus (HIV), herpes simplex virus (HSV), human
herpes virus 6 (HHV6), Epstein-Barr virus (EBV)] were
negative, as well as blood serologies (HIV, parvovirus B19)
and blood cultures. Toxicological analysis was only
positive for benzodiazepines. The electroencephalo-
gram (performed when our patient was already extu-
bated and alert) showed no sign of epilepsy.
The hemodynamical and neurological courses were
quickly favorable, allowing for an extubation and a
transfer to a regular hospital ward within 24 hours. A
clinical examination after extubation was strictly normal,
including complete neurological status, and our patient
was symptom-free.
Our patient could not recall what happened on the
day he lost consciousness. Given our suspicion of
heatstroke and the lack of evidence for an infectious
disease, antibiotics and antivirals were stopped. His
history was completed. Our patient had spent several
hours in an unusually hot environment 3 days before
the admission, while attending a meeting under a
tent. It has to be pointed out that the weather had
been exceptionally hot in Switzerland during this
period of time, with temperatures reaching record
levels. When specifically asked about his sweating,
our patient immediately reported a decrease in his
sweating since he started to take topiramate, while he
used to sweat profusely before.
The clinical and biological courses were uneventful,
with a normalization of all the parameters within 1
week, except for his gamma-glutamyl transpeptidase
Table 1 Laboratory values at admission and worst values within 48 hours
Test Unit Value at admission Worst value within 48 h Value one week later
Hemoglobin g/L 101 101 128
Leukocytes G/L 20.6 20.6 7.3
Thrombocytes G/L 181 131 377
PTT seconds >140 >140 25.5
INR 1.05 1.04 0.9
CRP mg/L 2.5 6.4 5.1
Creatinine umol/L 151 91 76
CK U/L 160 829 50
AST U/L 30 137 17
ALT U/L 34 346 64
Alkaline phosphatase U/L 39 48 72
GGT U/L 122 183 112
Total bilirubin umol/L 4 9 6
D day, PTT partial thromboplastin time, INR international normalized ratio, CRP C-reactive protein, CK creatine kinase, AST aspartate aminotransferase, ALT alanine
transaminase, GGT gamma-glutamyl transpeptidase
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(GGT) level, which remained at the upper limits of
normal, as already noted by his physician in the past.
Discussion
Heatstroke is a life-threatening condition resulting in
failure of normal compensatory heat-shedding mecha-
nisms. When heat gain exceeds heat loss, the body
temperature rises and can lead to heatstroke, defined as
a body temperature higher than 40 °C (104 °F) associated
with neurological dysfunction, ranging from mild altered
mental status to coma [1]. Two forms of heatstroke can
be distinguished: exertional and classical. Given the lack
of evidence of strenuous exercise in our patient, al-
though his profession could imply some physical efforts,
classical heatstroke seems to better correspond to his
condition: high temperature, coma, coagulation disorder,
rhabdomyolysis, hepatic injury, and renal failure.
Topiramate is an antiepileptic agent with a broad
spectrum of mechanisms of action, since blockage of
voltage-dependent sodium channels, augmentation of
gamma-aminobutyrate acid activity, antagonism of
AMPA/kainate receptors, and inhibition of the carbonic
anhydrase enzyme are known to contribute to its clinical
efficacy [3]. Topiramate is indicated to treat certain types
of seizures and to prevent migraine headaches [4]. More-
over, topiramate has also been recently designated as a
first-line agent in the treatment of essential tremor [5].
The usual side effects of topiramate are nausea, fatigue,
weight loss and paresthesia, but case reports in epileptic
children have raised concerns about the risk of hypohidro-
sis and heatstroke [6–8].
The postulated mechanism of topiramate-associated
hypohidrosis is thought to be related to an inhibition of
the carbonic anhydrase enzyme within the sweat glands,
leading to an impaired sweat composition with a re-
duced water formation and an impaired sweat rate. This
hypothesis is supported by small electrophysiological
studies showing that autonomic functions are normal in
children and adults presenting topiramate-associated
hypohidrosis [9, 10]. Moreover, research in mice sug-
gested that topiramate reduces aquaporin expression in
sweat glands.
Most of the hypohidrosis cases reported among chil-
dren taking topiramate showed a good clinical evolu-
tion when the drug was stopped [6, 7]. Regarding
adults, we found only six cases of patients diagnosed
with topiramate-related heatstroke, with unfavorable
outcome for half of them (one death and two with per-
sistent neurological dysfunction) [11–13]. The other
half, as well as our patient, completely recovered [14].
Doses of topiramate ranged between 200 and 600 mg/day.
Four patients were treated for seizures, one for migraine
and one for aggressive behavior. In a prospective, con-
trolled cohort study, 10.5 % of patients on topiramate
spontaneously reported hyperthermia when they were
asked about side effects in general compared to 0.5 % of
patients on other antiepileptics [15]. Described risk factors
to develop topiramate-associated hyperthermia are young
age, high doses and hot weather [15].
In our patient’s case, the dosage of topiramate was ra-
ther low, but our patient was taking ibuprofen, mefe-
namic acid, losartan and diuretics, which probably
contributed to acute renal failure in this diabetic patient,
potentially leading to an accumulation of topiramate,
since this drug is eliminated by the kidney. Unfortu-
nately, topiramate blood levels were not requested at ad-
mission. They were low (9.9 umol/L, normal 15–80
umol/L) 2 days later, after decreasing the dosage from
50 mg twice a day to 50 mg once a day. Second, the
weather on the day of admission and the past few days
had been exceptionally hot, reaching 39.7 °C (103.4 °F)
on the day of admission.
Regarding the results of the lumbar puncture, there
are no clear data describing how the CSF composition
should evolve during a heatstroke. Among the six other
adult patients diagnosed with topiramate-related heat-
stroke, four of them had had a lumbar puncture [11, 14]
which was described as normal and sterile. The albumi-
nocytologic dissociation we found may be explained by
the inflammatory state, leading to an enhanced perme-
ability of the membranes and an exudation of proteins
into the CSF, as would be observed during systemic in-
flammation response syndrome (SIRS).
Our patient had a cerebral CT scan described as
normal, which coincides with the other cases reported
[11, 14]. Only one patient with persistent neurological
dysfunction benefited from a cerebral magnetic reson-
ance imaging (MRI) scan [11], which showed diffuse
bilateral lesions, disappearing with time. However, a dif-
fuse atrophy persisted, suggesting irreversible neural dam-
age. We did not perform an MRI scan on our patient
given his complete neurological recovery.
Since our patient was taking a selective serotonin re-
uptake inhibitor at a therapeutic dosage on the day of
admission, the clinical manifestations (encephalopathy
and hyperthermia) could have raised the suspicion of
serotonin syndrome. Our patient was in a comatose state
and needed to be quickly intubated, therefore the initial
neurological examination was restricted, but clonus and
hyperreflexia were not specifically documented. Sero-
tonin syndrome was ruled out because citalopram had
always been well tolerated before, and its dosage had
remained unchanged over the past few weeks before ad-
mission. In addition, citalopram is partly metabolized by
the cytochrome P450 CYP3A4, which is induced by
topiramate. Given this mechanism, the recent introduc-
tion of topiramate would have theoretically led to a de-
crease of citalopram plasma concentration, thus further
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reducing the likelihood of serotonin syndrome. More-
over, the encephalopathy and hyperthermia resolved des-
pite citalopram continuation.
Conclusions
In conclusion, we report the case of a heatstroke in
the context of topiramate treatment in an adult pa-
tient, with complete recovery. Unlike other case re-
ports of adult patients with acute, severe outcomes,
we were able to document CSF characteristics and
perform an extensive infection workup, thus increas-
ing the likelihood of the diagnosis and providing CSF
particularities in this condition.
Topiramate-related heatstroke has particularly been
described in epileptic children but must be as well rec-
ognized in adults treated for migraine and essential
tremor, with lower dosages. Outcomes may range from
total clinical recovery to persistent neurological dysfunc-
tion or death. The prescription of topiramate and the
follow-up of adult patients under this medication should
include an evaluation of hypohidrosis and hyperthermia
especially in contexts of high external temperature.
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